摘要
目的探讨我院鲍曼不动杆菌感染的临床分布及耐药情况,为临床合理应用抗菌药物提供依据。方法采用回顾性方法对我院2007年1月-2009年12月住院的肿瘤病人临床标本中分离的128株鲍曼不动杆菌,对19种抗菌药物耐药性分析。结果 128株鲍曼不动杆菌感染主要发生在ICU病房、其次为内科,在临床标本中以肺癌病人痰液和咽拭子为主(82.03%),近年对19种抗菌药物耐药率有上升趋势,对美洛培南、哌拉西林/他唑巴坦、左氧氟沙星、头孢吡肟耐药率较低(<10%),对其余15种抗菌药物耐药率较高(均>30%)。结论美洛培南仍为鲍曼不动杆菌感染首选药,临床上鲍曼不动杆菌的耐药形势严峻,应加强对该菌耐药性监测,减少耐药菌的发生。
Objective To explore the clinical distribution and drug resistance of Acinetobacter baumannii infection in Hunan Tumor Hospital,and to provide the evidence for rational use of antibiotics in clinical application.Methods Totally 128 strains of Acinetobacter baumannii isolated from clinical samples of inpatients with tumor in Hunan Tumor Hospital from January,2007 to December,2009 were retrospectively analyzed,and the drug resistances to 19 kinds of antibiotics were analyzed too.Results The Acinetobacter baumannii infection occurred mainly in ICU wards,followed by department of internal medicine.The majority of clinical specimens （82.03%） were sputum and throat swabs collected from patients with lung cancer.The drug resistance rates to 19 kinds of antimicrobial agents were on the rise in recent years.The susceptibility rates of Acinetobacter baumannii to meropenem,piperacillin/tazobactam,levofloxacin,and cefepime were all less than 10%,while the susceptibility rates of Acinetobacter baumannii to other 15 kinds of antibiotics were all more than 30%.Conclusions Meropenem is still the first choice for Acinetobacter baumannii infection.The situation of drug resistance of Acinetobacter baumannii is severe,and therefore it is necessary for medical professionals to monitor the drug resistance of bacteria and to reduce the incidence of resistant isolates.
出处
《实用预防医学》
CAS
2010年第6期1197-1198,共2页
Practical Preventive Medicine
关键词
鲍曼不动杆菌
耐药性
抗菌药物
Acinetobacter baumannii
Drug resistance
Antibiotics
